SPEB Adhesives (SPEB)

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 37.12% suggests strong return on capital employed if the reported figures are reliable.
• Promoter holding of 73.18% aligns management interests with minority shareholders.
• P/E of 19.44 is not extreme for a specialty chemicals business, provided earnings normalize.
• Current price of ₹55.90 is closer to the 52-week low of ₹50.10 than the high of ₹98.25, reducing market expectations.

Concerns

• Latest reported quarter shows sales and net profit of ₹0 Cr, making ongoing operations unproven.
• Piotroski F-Score of 3/9 points to weak financial health and possible red flags.
• Zero sales growth, zero profit growth, and zero dividend offer no current compensation to shareholders.
• Insufficient data—no book value, ROE, or debt/equity—prevents any reliable margin-of-safety calculation.

AI Analysis

Let me start with what I know: SPEB Adhesives is a small specialty chemicals player with a market cap of ₹117 crore, trading at ₹55.90. The return on capital employed of 37.12% is eye-catching; it suggests the business, at some level, knows how to generate profits from invested capital. Promoter holding of 73.18% is also comforting—those running it have plenty of skin in the game. But my mentor taught me to spend more time on the downside. Here the red flags are considerable. The latest reported quarter shows zero sales and zero net profit—that is not a functioning compounding machine. Trailing P/E of 19.44 may look reasonable, but with reported sales and profit growth of exactly zero and no dividend, I am being paid nothing for the wait. The Piotroski F-Score of 3 out of 9 reinforces my suspicion: financial health is poor, and there may be hidden problems. Without book value, without return on equity, without debt-equity data, I cannot calculate a margin of safety. The stock is nearer its 52-week low of ₹50.10 than its high of ₹98.25, but cheapness for its own sake is not enough. In Warren's words, it's far better to buy a wonderful company at a fair price than a fair company at a wonderful price. This looks like a possible turnaround situation, not a proven operating business. I need evidence of real sales, real profits, and improving fundamentals before I risk capital. Until then, this is a pass for me.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer